Blood pressure and cardiovascular risk prediction in patients with diabetes mellitus: an introduction

Cushman WC, Evans GW, Byington RP et al. [The Accord Study group]. Effects of Intensive Blood Pressure-Control in Type 2 Diabetes Mellitus. N Engl J Med 2010; 362(17): 1575–1585. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1001286>.

Cheng Y, Wang D, Yang Y et al. Prognostic significance of systolic blood pressure time in target range in patients with type 2 diabetes mellitus. Res Square 2022 (preprint). Dostupné z DOI: <http://dx.doi.org/10.21203/rs.3.rs-1943479/v1>.

Nagajaran N, Townsend RR. Time in therapeutic range: timely in hypertension therapeutics? J Hum Hypertens 2023; 37(3): 244–247. Dostupné z DOI: <http://dx.doi.org/10.1038/s41371–022–00800-y>.

Dukát A (ed). Ambulantné monitorovanie krvného tlaku v klinickej praxi. FAMA: Brno 2020. ISBN 978–80–904731–6-4.

Niranen T, Mäki J, Puuka P et al. Office, home, and ambulatory blood pressure as predictors of cardiovascular risk. J Am Soc Hypertens 2014; 64(2): 281–286. Dostupné z DOI: <http://dx.doi.org/10.1161/HYPERTENSIONAHA.114.03292>.

Mancia G, Kreutz R, Brunström M et al. 2023 ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension. Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens 2023; 41(12): 1874–2071. Dostupné z DOI: <http://dx.doi.org/10.1097/HJH.0000000000003480>.

Banegas RJ, Ruilope LM, de la Siera A et al. Relationship between Clinic and Ambulatory-Blood Pressure Measurements and Mortality. N Engl J Med 2018; 378(16): 1509–1520. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1712231>. Retraction in Retraction: Banegas JR, Ruilope LM, de la Sierra A et al. N Engl J Med 2020; 382(8): 786. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMc2001445>.

Towsend RR. The Value in an Ambulatory Blood-Pressure Registry. N Engl J Med 2018; 378(16): 1555–1556. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMe1802369>.

Chobanian AV, Bakris GL, Black HR et al. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure JNC-7, Hypertension 2003; 42(6): 1206–1252. Dostupné z DOI: <http://dx.doi.org/10.1161/01.HYP.0000107251.49515.c2>.

Whelton PK, Carey RM, Aronow WS et al. 2017 ACC/AHA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 2018; 71(6): e13-e115. Dostupné z DOI: <http://dx.doi.org/10.1161/HYP.0000000000000065>. Correction to: 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 2018; 71(6): e140-e144. Dostupné z DOI: <http://dx.doi.org/10.1161/HYP.0000000000000076>.

Roush G, Fagard R, Salles G et al. Prognostic impact of clinic, daytime, and night-time systolic blood pressure in 9 cohorts of 13,843 patients with hypertension: systematic review and meta-analysis. J Am Soc Hypertens 2014; 32(12): 2332–2340; discussion 2340. Dostupné z DOI: <http://dx.doi.org/10.1097/HJH.0000000000000355>.

Hermida RC, Crespo JJ, Dominguez-Sardiňa M et al. Bedtime Hypertension Treatment Improves Cardiovascular Risk Reduction: Hygia Chronotherapy Trial. Eur Heart J 2020; 41(48): 4565–4576. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehz754>.

Serinel Y, Yee BJ, Grunstein RR et al. Chronotherapy for hypertension in obstructive sleep apnoea (CHOSA): a randomised, double-blind, placebo-controlled crossover trial. Thorax 2017; 72(6): 550–558. Dostupné z DOI: <http://dx.doi.org/10.1136/thoraxjnl-2016–209504>.

Blom K, Baker B, How M et al. Hypertension Analysis of Stress Reduction Using Mindfulness Meditation and Yoga: Results from the Harmony Randomised Clinical Trial. Am J Hypertens 2014; 27(1): 122–129. Dostupné z DOI: <http://dx.doi.org/10.1093/ajh/hpt134>.

Garrison SR, Kolber MR, Allan GM et al. Bedtime versus morning use of antihypertensives for cardiovascular risk reduction (BedMed): protocol for a prospective, randomised, open-label, blinded end-point pragmatic trial. BMJ Open 2022; 12(2): e059711. Dostupné z DOI: <http://dx.doi.org/10.1136/bmjopen-2021–059711>.

Mackensie IS, Rogers A, Poulter NR et al. Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the UK (TIME study): a prospective, randomized, open-label, blinded-endpoint clinical trial. Lancet 2022; 400(10361): 1417–1425. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(22)01786-X>.

Unger T, Borghi C, Charchar F et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension 2020; 75(6): 1334–1357. Dostupné z DOI: <http://dx.doi.org/10.1161/HYPERTENSIONAHA.120.15026>.

Hermida RC, Ayala DE, Mojon A et al. Influence of circadian time of blood pressure-lowering treatment on cardiovascular risk in resistant hypertension. European Renal Association/European Dialysis and Transplant Association 2011 Congress June 25, 2011, Prague. Abstract Sa030.

Hermida RC, Ayala DE, Mojón A et al. Influence of circadian time of hypertension treatment on cardiovascular risk. Results from the MAPEC study. Chronobiol Int 2010; 27(8): 1629–1651. Dostupné z DOI: <http://dx.doi.org/10.3109/07420528.2010.510230>.

Mathur P, Kadavath S, Marsh JD et al. Chronotherapy for Hypertension: Improvement in Patient Outcomes with Bedtime Administration of Antihypertensive Drugs. Eur Heart J 2020; 41(48): 4577–4579. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehz836>.

Kimura G. Kidney and circadian blood pressure rhythm. Hypertension 2008; 51(4): 827–828. Dostupné z DOI: <http://dx.doi.org/10.1161/HYPERTENSIONAHA.108.110213>.

Hermida RC, Ayala DE, Mojón A et al. Bedtime ingestion of hypertension medications reduces the risk of new-onset type 2 diabetes: a randomised controlled trial. Diabetologia 2016; 59(2): 255–265. Dostupné z DOI: <http://dx.doi.org/10.1007/s00125–015–3749–7>.

Hermida CR, Ayala DE, Mojón A et al Risk incident chronic kidney disease is better reduced by bedtime than upon-awakening ingestion of hypertension medications. Hypertens Res 2018; 41(5): 342–353. Dostupné z DOI: <http://dx.doi.org/10.1038/s41440–018–0029–1>.

Wang C, Ye Y, Liu C et al. Evening versus morning dosing regimen drug therapy foe kidney disease patients with hypertension in blood pressure patterns: a systematic review and meta-analysis. Intern Med J 2017; 47(8): 900–906. Dostupné z DOI: <http://dx.doi.org/10.1111/imj.13490>.

Bowles NP, Thosar SS, Herzig MX et al. Chronotherapy for hypertension. Curr Hypertens Rep 2018; 20(11): 97. Dostupné z DOI: <http://dx.doi.org/10.1007/s11906–018–0897–4>. Erratum in Correction to: Chronotherapy for Hypertension. Bowles NP, Thosar SS, Herzig MX et al. Curr Hypertens Rep 2018; 21(1):1. Dostupné z DOI: <http://doi: 10.1007/s11906–018–0905–8>.

Bakris G. Time in Therapeutic Range: Redefining „Optimal“ Blood Pressure Control. J Am Cooll Cardiol 2021; 77(10): 1300–1301. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2021.01.019>.

Wang N, Harris K, Hamet P et al. Cumulative Systolic Blood Pressure Load and Cardiovascular Risk in Patients with Diabetes. J Am Coll Cardiol 2022; 80(12):1147–1155. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2022.06.039>.